TxCell develops innovative, personalized cellular immunotherapies using regulatory T cells (Treg).

TxCell is exclusively developing regulatory T cells that are specific of a single antigen.

As shown below, our general process starts with a simple blood collection. From this blood sample, we produce antigen-specific Treg cells and then expand them before injecting them back to the patient.

TxCell is developing two proprietary technology platforms, ENTrIA, which is composed of genetically-engineered Tregs, and ASTrIA, which is composed of non-modified naturally antigen-specific Tregs.

Our dual platform has the potential to address a wide range of severe inflammatory and autoimmune disorders with unmet medical needs. TxCell’s current targets include transplant rejection, Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis.